T1	p 84 119	advanced nasopharyngeal carcinoma :
T2	p 202 219	carcinoma ( NPC )
T3	p 259 266	tumor .
T4	p 382 410	patients with advanced NPC .
T5	p 432 537	From December 1993 to April 1999 , 284 patients with 1992 American Joint Committee on Cancer stage III to
T6	p 543 551	M0 ) NPC
T7	p 1653 1657	nine
T8	p 1687 1688	>
T9	p 1713 1717	nine
T10	p 1727 1728	.
T11	p 1845 1890	patients with advanced NPC in endemic areas .
T12	i 25 79	concurrent chemoradiotherapy versus radiotherapy alone
T13	i 319 378	chemoradiotherapy ( CCRT ) versus radiotherapy ( RT ) alone
T14	i 628 630	RT
T15	i 710 756	concurrent chemotherapy with cisplatin 20 mg/m
T16	i 763 792	/d plus fluorouracil 400 mg/m
T17	i 813 823	continuous
T18	i 1258 1262	CCRT
T19	i 1286 1293	RT-only
T20	i 1376 1380	CCRT
T21	i 1416 1423	RT-only
T22	i 1614 1637	concurrent chemotherapy
T23	i 1812 1816	CCRT
T24	i 1832 1840	RT alone
T25	o 139 178	overall and progression-free survival .
T26	o 866 883	Survival analysis
T27	o 1141 1154	tumor relapse
T28	o 1208 1237	5-year overall survival rates
T29	o 1317 1355	5-year progression-free survival rates
T30	o 1473 1481	toxicity
T31	o 1520 1554	leukopenia and emesis , compliance
T32	o 1761 1767	deaths